AES Annual Meeting Digital Select 2026
Available for purchase: July 22, 2026, and will close on November 15, 2027
Course start date: 12/15/2026
Course End date: 12/14/2027
About This Course
The AES Annual Meeting/Digital Select provides high-quality, relevant educational programming across diverse settings, roles, and experience levels. Whether you are new to the specialty, have limited epilepsy background, or are highly proficient with complex topics, you will find sessions and content that meet your needs.
Statement of Need
The need for this activity has been determined based on identifying professional practice gaps, previous course evaluations, and AES self-assessments, we established the need for this activity. The content reflects current issues and topics provided by the Annual Meeting Committee and AES members to ensure relevance to the audience.
Target Audience
Neurologists, epileptologists, pediatric neurologists, nurses, psychologists, neuropsychologists, nurse practitioners, physician assistants, pharmacists, researchers, and scientists.
Global Learning Objectives
This comprehensive educational meeting provides learners with opportunities to:
- Expand knowledge of epilepsy diagnosis and treatment, including new diagnostic methods, therapeutic options, and common comorbidities, to improve clinical practice and patient outcomes.
- Stay informed about recent epilepsy research with potential short-term clinical applicability.
- Reflect on the public health burden of epilepsy and its effects on patients, communities, and health systems. Note: Individual session learning objectives are available for review on AES Learn.
NOTE: Each session has its own specific learning objectives available for review on AES Learn.
Mission Statement
The American Epilepsy Society (AES) promotes research and education for physicians and other healthcare professionals dedicated to the prevention, treatment, and cure of epilepsy. Its continuing professional education (CPE) offers an array of activities to assist the learner in assessing their educational needs and expanding their knowledge, competence and performance in the field of epilepsy, which leads to an improvement in the outcomes of care.
The CPE program always reinforces the fundamental components of epilepsy care in accordance with an Epilepsy Core Curriculum, including quality improvement and patient safety. In addition, its educational interventions also provide an opportunity to advance professional practice in new and emerging areas of the specialty. In recognition of the importance of the added qualification in epilepsy by the American Board of Psychiatry and Neurology as well as the Maintenance of Certification requirements, AES is committed to the provision of educational opportunities and tools that aid in the certification and MOC requirements.
The expected results of AES s program of continuing professional development are as follows:
- AES's CPE Program fosters a culture of interprofessional collaboration amongst the cadre of professionals that care for persons with epilepsy.
- AES's CPE Program enhances the professional practice of healthcare professionals who care for persons with epilepsy.
- The AES's CPE Program provides education in epilepsy therapy to increase the competence of clinicians in the use of these complex and multi-layered options to manage epilepsy in patients.
- The AES's CPE Program uses educational interventions as a tool to improve the quality of care and patient safety of persons with epilepsy.
Accreditation
This enduring activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education. The American Epilepsy Society (AES) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Disclosure Policy and Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity, and scientific rigor. All individuals involved in the selection, development, and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with an ineligible company. AES has implemented the mechanisms of prospective peer review of this CME activity to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.
Unapproved Use Disclosure
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.
Disclaimer
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational, and/or experimental uses.